Private Equity
Boston-based Ginkgo Bioworks, an organism company, has raised $275 million in Series D funding. The investors included Viking Global, Y Combinator's Continuity Fund, Cascade Investment and General Atlantic.
1 min read · 14 December 2017
Oakland, California-based Elemeno Health, a digital health startup, has secured $1.3 million in seed funding. Launchpad Digital Health led the round.
1 min read · 14 December 2017
Los Altos, California-based Cibiem Inc, a medical device company, has appointed William H. Kucheman to its board of directors. Currently, Kucheman served as director of BioStar Ventures III, a medical device venture capital fund. Cibiem is backed by Third Rock Ventures, SV Health Investors and BioStar Ventures.
3 min read · 14 December 2017
Menlo Park, California-based GRAIL Inc, a life sciences company focused on detecting cancer early when it can be cured, has named Jennifer Cook as CEO. Her appointment becomes effective January 2, 2018. Bill Rastetter, the interim CEO since August 2017, will continue as chairman of the board of directors. And GRAIL has added Catherine Friedman and Min Cui to its board of directors. GRAIL's backers include ARCH Venture Partners, Amazon, Bezos Expeditions, Bill Gates, Bristol-Myers Squibb, Celgene, Decheng Capital, GV, Illumina, Johnson & Johnson Innovation, Merck, McKesson Ventures, Sutter Hill Ventures, Tencent and Varian Medical Systems.
5 min read · 14 December 2017
Cambridge, Massachusetts-based Relay Therapeutics, a biotech company, has closed $63 million in Series B financing. BVF Partners led the round with participation from GV, Casdin Capital, EcoR1 Capital, Section 32, Third Rock Ventures and Alexandria Venture Investments. In conjunction with the funding, Kanishka Pothula, a managing director at BVF Partners, will join Relay Therapeutics' board of directors.
1 min read · 14 December 2017
Cambridge, Massachusetts-based Kyn Therapeutics, a provider of new immunometabolism therapies for treating cancer, has secured $49 million in Series A funding. The investors were Atlas Venture and OrbiMed.
1 min read · 14 December 2017
2 min read · 14 December 2017
1 min read · 14 December 2017
UK-based Atlas Genetics, a near patient and point-of-care testing company, has named Marc Jones as chief operating officer and chief financial officer. Previously, Jones worked at Good Start Genetics, where he served as COO and CFO. Atlas Genetics is backed by Novartis Venture Fund, Consort Medical, Wondfo Biotech, LSP Venture Capital, BB Biotech, Johnson & Johnson Innovation, RMI Investments and Southwest Ventures Fund.
3 min read · 13 December 2017
New Albany, Ohio-based Myonexus Therapeutics Inc, a developer of transformative gene therapies for limb-girdle muscular dystrophies, has closed $2.5 million in seed financing. The investors included CincyTech LLC, Rev1 Ventures, The Jain Foundation and GFB ONLUS.
1 min read · 13 December 2017
